Phase II study of tazemetostat for relapsed or refractory B‐cell non‐Hodgkin lymphoma with EZH2 mutation in Japan

Tazemetostat is a selective, reversible, small‐molecule inhibitor of the histone methyltransferase enzyme, enhancer of zest homolog 2 (EZH2). In this multicenter, open‐label, phase II study, we assessed the efficacy and safety of tazemetostat in Japanese patients with relapsed or refractory (R/R) B‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Izutsu, Koji, Ando, Kiyoshi, Nishikori, Momoko, Shibayama, Hirohiko, Teshima, Takanori, Kuroda, Junya, Kato, Koji, Imaizumi, Yoshitaka, Nosaka, Kisato, Sakai, Rika, Hojo, Seiichiro, Nakanishi, Tadashi, Rai, Shinya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409398/
https://www.ncbi.nlm.nih.gov/pubmed/34159682
http://dx.doi.org/10.1111/cas.15040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409398/
https://www.ncbi.nlm.nih.gov/pubmed/34159682
http://dx.doi.org/10.1111/cas.15040

Ejemplares similares